ArticleAmerican journal of blood research2026
Immunological, hematological and biochemical benefits of adjuvant nigella sativa to pharmacotherapy in immune thrombocytopenic purpura patients.
Article in American journal of blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02816957 (Study of The Therapeutic Benefits of Nigella Sativa in Children With Beta Thalassemia Major), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of The Therapeutic Benefits of Nigella Sativa in Children With Beta Thalassemia Major
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients having acute and chronic immune thrombocytopenic purpura (ITP) suffer from thrombocytopenia, decreased T regulatory lymphocytes (causing immunological tolerance) and abnormal biochemistry (increased inflammatory mediators, autoimmunity, and oxidative stress). Nigella sativa is a prophetic medicine remedy rich in pharmacological ingredients exerting anti-inflammatory and thrombocytosis effects that may improve the biochemistry of ITP patients.
objectiveTo evaluate the benefits of nigella sativa to ITP patients.
methodsEthical committee approval and patients' consents were gained and complied with the declaration of Helsinki. Children's parents or legal guardians provided informed consent. 15 acute ITP patients received steroids or Eltrombopag olamine (revolade) for one month then complete blood count was done in addition to counting CD4 T helper cells and Treg cells using flow cytometry. Then, same patients continued the same treatments plus adjuvant 2 grams/day grinded nigella sativa seeds (taken orally added to foods or drinks) for the next month followed by doing the same blood tests. Another 15 patients having chronic ITP received same treatments and investigations.
resultsIn acute ITP patients on steroids or revolade, platelets count was low (29.26±5.88 × 10
conclusionAdjuvant nigella sativa potentiated pharmacological treatments, exerted potent thrombocytosis effects and increased immunological tolerance in acute and chronic ITP patients possibly due to its anti-inflammatory, immunomodulatory and biochemical effects. Nigella sativa is a recommended adjuvant natural remedy to ITP patients. This study is registered among our hematological studies using nigella sativa in treating hematological diseases in ClinicalTrials.gov. TRIAL ID: NCT02816957.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.